Details
Title
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy
Author
Burke, G. A. Amos 1 ; Beishuizen, Auke 2 ; Bhojwani, Deepa 3
; Burkhardt, Birgit 4
; Minard-Colin, Véronique 5 ; Norris, Robin E. 6 ; Kabickova, Edita 7 ; Pinarli, F. Guclu 8 ; Tacyildiz, Nurdan 9 ; Howes, Angela 10 ; Jong, Jan de 11 ; Liu, Grace 12 ; Nottage, Kerri 12 ; Salman, Mariya 12 ; Trixhe, Xavier Woot de 13 ; Cairo, Mitchell 14
1 Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Department of Paediatric Haematology, Oncology and Palliative Care, Cambridge, UK (GRID:grid.120073.7) (ISNI:0000 0004 0622 5016)
2 Princess Máxima Center for Pediatric Oncology, Department of Hematology and Oncology, Utrecht, Netherlands (GRID:grid.487647.e)
3 University of Southern California, Keck School of Medicine, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
4 University Hospital Münster, Pediatric Hematology and Oncology, Münster, Germany (GRID:grid.16149.3b) (ISNI:0000 0004 0551 4246)
5 Department of Child and Adolescent Cancer, Gustave Roussy, Paris, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
6 University of Cincinnati College of Medicine, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, Cincinnati, USA (GRID:grid.239573.9) (ISNI:0000 0000 9025 8099)
7 Charles University and University Hospital Motol, Department of Pediatric Hematology and Oncology, Prague, Czech Republic (GRID:grid.412826.b) (ISNI:0000 0004 0611 0905)
8 Gazi University, Department of Pediatric Oncology, Ankara, Turkey (GRID:grid.25769.3f) (ISNI:0000 0001 2169 7132)
9 Ankara University, Department of Pediatric Hematology and Oncology, Ankara, Turkey (GRID:grid.7256.6) (ISNI:0000 0001 0940 9118)
10 Janssen R&D LLC, Clinical Oncology, High Wycombe, UK (GRID:grid.507827.f)
11 Janssen R&D LLC, Clinical Pharmacology, San Diego, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927)
12 Janssen R&D LLC, Clinical Oncology, Raritan, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927)
13 Janssen R&D LLC, Pharmacometrics, Beerse, Belgium (GRID:grid.497530.c)
14 New York Medical College, Department of Pediatrics, Medicine, Pathology, Microbiology and Immunology and Cell Biology and Anatomy, Valhalla, USA (GRID:grid.260917.b) (ISNI:0000 0001 0728 151X)
; Burkhardt, Birgit 4
; Minard-Colin, Véronique 5 ; Norris, Robin E. 6 ; Kabickova, Edita 7 ; Pinarli, F. Guclu 8 ; Tacyildiz, Nurdan 9 ; Howes, Angela 10 ; Jong, Jan de 11 ; Liu, Grace 12 ; Nottage, Kerri 12 ; Salman, Mariya 12 ; Trixhe, Xavier Woot de 13 ; Cairo, Mitchell 14 1 Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Department of Paediatric Haematology, Oncology and Palliative Care, Cambridge, UK (GRID:grid.120073.7) (ISNI:0000 0004 0622 5016)
2 Princess Máxima Center for Pediatric Oncology, Department of Hematology and Oncology, Utrecht, Netherlands (GRID:grid.487647.e)
3 University of Southern California, Keck School of Medicine, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
4 University Hospital Münster, Pediatric Hematology and Oncology, Münster, Germany (GRID:grid.16149.3b) (ISNI:0000 0004 0551 4246)
5 Department of Child and Adolescent Cancer, Gustave Roussy, Paris, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
6 University of Cincinnati College of Medicine, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, Cincinnati, USA (GRID:grid.239573.9) (ISNI:0000 0000 9025 8099)
7 Charles University and University Hospital Motol, Department of Pediatric Hematology and Oncology, Prague, Czech Republic (GRID:grid.412826.b) (ISNI:0000 0004 0611 0905)
8 Gazi University, Department of Pediatric Oncology, Ankara, Turkey (GRID:grid.25769.3f) (ISNI:0000 0001 2169 7132)
9 Ankara University, Department of Pediatric Hematology and Oncology, Ankara, Turkey (GRID:grid.7256.6) (ISNI:0000 0001 0940 9118)
10 Janssen R&D LLC, Clinical Oncology, High Wycombe, UK (GRID:grid.507827.f)
11 Janssen R&D LLC, Clinical Pharmacology, San Diego, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927)
12 Janssen R&D LLC, Clinical Oncology, Raritan, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927)
13 Janssen R&D LLC, Pharmacometrics, Beerse, Belgium (GRID:grid.497530.c)
14 New York Medical College, Department of Pediatrics, Medicine, Pathology, Microbiology and Immunology and Cell Biology and Anatomy, Valhalla, USA (GRID:grid.260917.b) (ISNI:0000 0001 0728 151X)
Pages
2271-2275
Publication year
2020
Publication date
Aug 2020
ISSN
08876924
e-ISSN
14765551
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2475005208
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.